Real-World Study of Senaparib for First-Line Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600120564

Enrollment

Unknown

Registered

2026-03-17

Start date

2026-03-18

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

Interventions

Senaparib group:NA

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old. 2. Patients with newly diagnosed FIGO Stage II-IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. 3. Patients who have achieved complete response (CR) or partial response (PR) after first-line platinum-based chemotherapy . 4. Investigator-assessed eligibility for senaparib treatment regimen, combination with other agents is permitted. 5. Voluntary informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Confirmed pregnancy or lactating women; 2. Any other conditions deemed by the investigator as unsuitable for study enrollment.

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS);	—

Secondary

Measure	Time frame
safety;Overall Survival;	—

Countries

China

Contacts

Public ContactLei Li

Peking Union Medical College Hospital

lilei@pumch.cn+86 10 69156204

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026